Hims & Hers falls 8% after Novo's legal threat. Here's the latest [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
Hims is launching its pill for as little as $49, significantly lower than the $149 Novo sells the branded pill for. Hims is a volatile stock, inherently tied to its perceived ability to sell weight loss drugs like its Wegovy copy. In this article Rafael Henrique | SOPA Images | AP The stock of Hims & Hers dropped in premarket trading early Friday after a legal threat from Novo Nordisk The online teleheath company announced on Thursday plans to launch a cheaper, copycat version of Novo's weight loss pill, prompting Novo to take legal action. Hims stock spiked as much as 15% on the news in Thursday trading, but quickly pared gains and ended the session down 3.8% at a 12-month low after Novo said the action was “illegal.” Shares fell another 6.7% in premarket trading Friday. Hims said it will launch a Wegovy-style pill containing the same active ingredient as the original brand, semaglutide, for as little as $49 for the first month when customers sign up for a subscription
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- TrumpRx: See the 43 drugs available on the Trump administration's new discounted drug site [CBS News]CBS News
- Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore [Yahoo! Finance]Yahoo! Finance
- Hims & Hers shares tick lower after Novo's legal threat [MSNBC.com]MSNBC.com
- Many 2026 Super Bowl ads share a common theme, revealing a truth about America's current mindset By Mae Anderson and The Associated Press By Mae Anderson and The Associated Press February 6, 2026, 2:06 PM ET [Fortune]Fortune
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- NVO's page on the SEC website